Recombinant multi-species TMEM86B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TMEM86B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Enables alkenylglycerophosphocholine hydrolase activity; alkenylglycerophosphoethanolamine hydrolase activity; and identical protein binding activity. Involved in ether lipid metabolic process. Located in cytoplasm and membrane. [provided by Alliance of Genome Resources, Apr 2022]
The Alternative Names of target: C330014O21Rik,Lysoplasmalogenase TMEM86B,TMEM86B,Tmem86b,Transmembrane protein 86B

Target products collectionGo to TMEM86B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP2134-Ag-1/ GM-Tg-hg-IP2134-Ag-2 Human TMEM86B protein Human
GM-Tg-rg-IP2134-Ag-1/ GM-Tg-rg-IP2134-Ag-2 Rat TMEM86B protein Rat
GM-Tg-mg-IP2134-Ag-1/ GM-Tg-mg-IP2134-Ag-2 Mouse TMEM86B protein Mouse
GM-Tg-cynog-IP2134-Ag-1/ GM-Tg-cynog-IP2134-Ag-2 Cynomolgus/Rhesus macaque TMEM86B protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP2134-Ag-1/ GM-Tg-felg-IP2134-Ag-2 Feline TMEM86B protein Feline
GM-Tg-cang-IP2134-Ag-1/ GM-Tg-cang-IP2134-Ag-2 Canine TMEM86B protein Canine
GM-Tg-bovg-IP2134-Ag-1/ GM-Tg-bovg-IP2134-Ag-2 Bovine TMEM86B protein Bovine
GM-Tg-equg-IP2134-Ag-1/ GM-Tg-equg-IP2134-Ag-2 Equine TMEM86B protein Equine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP2134-Ag-1/ GM-Tg-hg-IP2134-Ag-2; GM-Tg-rg-IP2134-Ag-1/ GM-Tg-rg-IP2134-Ag-2;
GM-Tg-mg-IP2134-Ag-1/ GM-Tg-mg-IP2134-Ag-2; GM-Tg-cynog-IP2134-Ag-1/ GM-Tg-cynog-IP2134-Ag-2;
GM-Tg-felg-IP2134-Ag-1/ GM-Tg-felg-IP2134-Ag-2; GM-Tg-cang-IP2134-Ag-1/ GM-Tg-cang-IP2134-Ag-2;
GM-Tg-bovg-IP2134-Ag-1/ GM-Tg-bovg-IP2134-Ag-2; GM-Tg-equg-IP2134-Ag-1/ GM-Tg-equg-IP2134-Ag-2
Products Name TMEM86B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name TMEM86B
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TMEM86B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.